Rate Video

EHA 2022 | Ongoing trials in AML and HR-MDS: ENHANCE, ENHANCE-2 and ENHANCE-3

Naval Daver • 11 Jun 2022

Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Antibodies Azacitidine Magrolimab Venetoclax

ENHANCE ENHANCE-2 ENHANCE-3

Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses three ongoing studies investigating various treatment combinations in acute myeloid leukemia (AML) and high-risk (HR) myelodysplastic syndromes (MDS), including the ENHANCE study (NCT04313881), the ENHANCE-2 study (NCT04778397), and the ENHANCE-3 study (NCT05079230). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Venetoclax plus idasanutlin for R/R AML: Phase I/II trial

Newly approved drugs for AML in the US

Naval Daver • 14 Jun 2018

CD47 antibodies for the treatment of AML and MDS: where is the field moving?

Naval Daver • 11 Jun 2022

Magrolimab with azacitidine in patients with AML

Naval Daver • 28 May 2020

Related Videos

Key challenges of using the intestinal microbiome as a biomarker

CAR T-cell therapy: the importance of LTFU

Somatic mutations in MDS as targets for therapy

Valeria Santini

Somatic mutations in MDS as a diagnostic and prognostic tool

Valeria Santini